Inceptor Bio
Inceptor Bio is a clinical-stage biotech developing CAR-T, CAR-M, and CAR-NK cell therapies for solid tumors, with lead program IB-T101 targeting CD70 in clear cell renal cell carcinoma. Pre-revenue, it earns milestone and royalty revenue via territorial licensing partnerships.
- Company typePrivate
- Founded2020
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Inceptor Bio does
Inceptor Bio is a clinical-stage biotechnology company founded in May 2020 and headquartered in Morrisville, North Carolina (Research Triangle Park). The company develops engineered cell therapies — spanning CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) modalities — for solid tumors. Its lead program, IB-T101, is an autologous CAR-T therapy directed at CD70-expressing cancers, with an initial indication in clear cell renal cell carcinoma (ccRCC); the first patient was dosed in February 2025 in a Phase 1 trial. The lead indication addresses a market of more than 300,000 new ccRCC cases annually worldwide.
The company's core technical differentiator is the OUTLAST™ platform, which metabolically reprograms T cells to persist and function within the hostile tumor microenvironment — a documented failure mode for conventional CAR-T therapies in solid tumors. Inceptor operates an in-house GMP manufacturing facility in Gainesville, Florida, acquired in 2022, providing process control and production independence for clinical supply. The pipeline also includes exploratory CAR-M and CAR-NK programs targeting the same CD70 antigen, and the company has established an in-house manufacturing footprint plus a series of preclinical data packages supporting the IB-T101 mechanism.
Inceptor is pre-revenue, with no approved or commercial products. Its business model is two-pronged: (1) internal development and eventual commercialization of proprietary cell therapies, either independently or with a future commercial partner, and (2) near-term licensing revenue through territorial partnerships — exemplified by its December 2024 deal with GRIT Bio granting China rights to IB-T101, which provides milestone and royalty upside. The company has raised approximately $84 million across multiple funding rounds since inception, with Kineticos Life Sciences as a consistent financial backer, and is led by CEO Matthias Schroff (formerly of Exicure) and Founder/Executive Chair Shailesh Maingi.
Inceptor Bio firmographics
Firmographics- Name
- Inceptor Bio
- Legal name
- Inceptor Bio, LLC
- Website
- https://inceptor.bio
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inceptor Bio is a clinical-stage biotech developing CAR-T, CAR-M, and CAR-NK cell therapies for solid tumors, with lead program IB-T101 targeting CD70 in clear cell renal cell carcinoma. Pre-revenue, it earns milestone and royalty revenue via territorial licensing partnerships.
- Ownership category
- akta.pro rank
Inceptor Bio industry classification
Industry- Product category
- Cell Therapy / Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), NK Cell Therapies (HLAAABAD)
Keywords
Where Inceptor Bio is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Inceptor Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Therapy Development and Commercialization: Pre-revenue clinical stage biotechnology company developing cell therapies for cancer treatment. Revenue expected from future therapeutic product sales upon regulatory approval.
- Partnership Milestones and Royalties: Receives milestone payments and royalties from GRIT Bio partnership upon IB-T101 achieving certain response criteria and regulatory milestones in China.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Inceptor Bio product offering
Product offeringCore offering
Inceptor Bio develops next-generation autologous cell therapies for solid tumors, with lead candidate IB-T101, a CD70-targeted CAR-T therapy for clear cell Renal Cell Carcinoma (ccRCC). Its proprietary OUTLAST™ platform metabolically reprograms T cells during manufacturing to thrive in the hostile tumor microenvironment, producing stem-like, exhaustion-resistant cells. The portfolio also includes CAR-M (macrophage) and CAR-NK (natural killer) cell therapy platforms in development.
Product overview
Inceptor Bio is a clinical-stage biotechnology company developing a diversified portfolio of next-generation cell therapies for solid tumors. The company's core offering consists of the proprietary OUTLAST™ platform, which metabolically reprograms T cells to overcome the hostile tumor microenvironment. The lead product candidate IB-T101 is an autologous CAR-T therapy targeting CD70 for clear cell Renal Cell Carcinoma (ccRCC). The technology portfolio includes CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) cell therapy platforms, all engineered to address the unique challenges of treating solid tumors that represent 90% of cancer cases.
Differentiator
Problem solved
Functional benefit
Brands
- OUTLAST™ Platform: Proprietary platform that metabolically reprograms T cells to thrive in the hostile tumor microenvironment by conditioning for the fittest, most persistent cells through controlled TME-like stress.
Products and services
- IB-T101 Autologous CAR-T cell therapy targeting CD70 for the treatment of clear cell Renal Cell Carcinoma (ccRCC), built on the OUTLAST™ platform to deliver stem-like, durable, exhaustion-resistant T cells for solid tumors.
- OUTLAST™ Platform Proprietary manufacturing platform that metabolically reprograms T cells by conditioning them in TME-like stress environments to produce stem-like, durable anti-tumor phenotypes with enhanced persistence, metabolic fitness, and resistance to exhaustion. All components are available at GMP grade.
- CAR-M Platform
Quantifiable outcome
- Superior preclinical efficacy demonstrated in aggressive RCC tumor model at low CAR-T doses and after tumor re-challenge
- +2 more outcomes
Companies that use Inceptor Bio
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Inceptor Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Inceptor Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GRIT BiocoreStrategic partnership to advance IB-T101, a potentially best-in-class CAR-T therapy targeting solid tumors. Inceptor grants GRIT Bio exclusive license for IB-T101 in China. GRIT Bio oversees development, manufacturing, and commercialization in China. Inceptor retains ex-China rights and is eligible for milestone payments and royalties upon IB-T101 achieving certain response criteria. Clinical data from this collaboration will support regulatory submissions and development in other regions.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Inceptor Bio competitors and assessment
Company assessmentDirect peers
- Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T and CAR-NK therapies, including in oncology indications. Directly comparable as a next-generation cell therapy developer targeting hematologic and solid tumors with engineered immune cell platforms.
- Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapy with multiple clinical-stage oncology programs. Comparable as a well-capitalized cell therapy developer pursuing off-the-shelf alternatives to autologous approaches like Inceptor's IB-T101.
- Nkarta: Clinical-stage biotech developing allogeneic and autologous CAR-NK cell therapies for cancer. Directly comparable through Inceptor's CAR-NK platform and shared focus on NK-based modalities for solid and hematologic tumors.
- Arcellx: Clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for cancer. Inceptor Bio advisor Chris Heery serves as Arcellx's CMO, illustrating direct operational and scientific overlap with Inceptor's CAR-T platform.
- Precision BioSciences: Clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T therapies using its ARCUS platform. Highly comparable given shared scientific leadership (Mike Nicholson, Chris Heery previously held senior roles there) and CAR-T oncology focus.
- Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable as a solid-tumor-focused cell therapy developer pursuing durable responses through engineered T-cell receptors.
- Fate Therapeutics: Clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell therapies for cancer. Comparable through its CAR-NK and engineered T-cell programs addressing solid tumors, with broader modality portfolio.
- Poseida Therapeutics: Clinical-stage cell therapy company developing CAR-T candidates including allogeneic and solid-tumor programs. Comparable as a CAR-T-focused oncology cell therapy developer advancing multiple clinical-stage programs.
Broad incumbents
- CRISPR Therapeutics: Larger clinical- to commercial-stage gene and cell therapy company with approved Casgevy and a broad CAR-T pipeline. Comparable as a major cell therapy competitor and potential acquirer of next-generation platforms like OUTLAST™.
- Bristol Myers Squibb (Cell Therapy / ex-Juno): Global oncology incumbent with multiple approved CAR-T products (Breyanzi, Abecma) inherited from the Juno Therapeutics acquisition. Multiple Inceptor board members and advisors previously led regulatory and process science at Juno/BMS, making it the most likely strategic acquirer or partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Inceptor Bio social profiles
Digital presenceInceptor Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inceptor Bio leadership team
Management profileNumber of profiles
Profiles11 records
Inceptor Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inceptor Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inceptor Bio
What does Inceptor Bio do?
Inceptor Bio develops next-generation autologous cell therapies for solid tumors, with lead candidate IB-T101, a CD70-targeted CAR-T therapy for clear cell Renal Cell Carcinoma (ccRCC). Its proprietary OUTLAST™ platform metabolically reprograms T cells during manufacturing to thrive in the hostile tumor microenvironment, producing stem-like, exhaustion-resistant cells. The portfolio also includes CAR-M (macrophage) and CAR-NK (natural killer) cell therapy platforms in development.
Is Inceptor Bio a public or private company?
Inceptor Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inceptor Bio founded?
Inceptor Bio was founded in 2020. It employs 11 to 50 people.
Where is Inceptor Bio based?
Inceptor Bio is headquartered in Raleigh, United States, in the North America region.
How does Inceptor Bio make money?
Two revenue lines are on record. Therapy Development and Commercialization is the primary driver. The others are partnership Milestones and Royalties.
Who are Inceptor Bio's main competitors?
Direct peers on record are Caribou Biosciences, Allogene Therapeutics, Nkarta, Arcellx, Precision BioSciences, Adaptimmune, Fate Therapeutics and Poseida Therapeutics. Broad incumbents are CRISPR Therapeutics and Bristol Myers Squibb (Cell Therapy / ex-Juno).
Does Inceptor Bio have an API?
No public API is recorded for Inceptor Bio.
What industry is Inceptor Bio in?
Inceptor Bio's product category is Cell Therapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.